H.C. Wainwright reaffirms Buy rating on Abeona Therapeutics stock at $20
PositiveFinancial Markets

H.C. Wainwright has reaffirmed its Buy rating on Abeona Therapeutics, setting a target price of $20 for the stock. This endorsement is significant as it reflects confidence in the company's potential for growth and success in the biotech sector, which could attract more investors and boost the stock's performance.
— Curated by the World Pulse Now AI Editorial System